The Next Generation of Lens Implants: What 2026 Research Tells Us About the Future of Cataract Surgery
By Dr Mayank Bansal, Vitreoretinal Surgeon | Updated October 2026 | 9-minute read
When patients sit across from me before cataract surgery, the most common question is no longer "Will I see again?" It is "Which lens should I choose?" Close behind it comes a newer question: "Is something better coming soon?"
That is a fair question. The artificial lens, or intraocular lens (IOL), has changed more in the last five years than in the twenty before that, and some of the most interesting work is still in clinical trials. This article explains what is being developed, what the 2026 research shows, and what it realistically means for you.
Why the Lens Implant Is Being Rethought
A standard IOL has a fixed power. We calculate that power before surgery from measurements of your eye, and modern formulas are very accurate. Even so, the eye heals in its own way, and a small number of patients end up slightly off target. Once a conventional lens is inside the eye, its power cannot be changed without another procedure.
The second limitation is focus. Your natural lens could change shape to shift focus from far to near. Artificial lenses cannot. Multifocal and extended-depth lenses get around this by splitting or stretching light, which works well for many people but can bring halos and glare at night.
The new technologies try to solve one or both of these problems.
1. Light-Adjustable Lenses: Fine-Tuning Your Vision After Surgery
Imagine trying on your new prescription for a few weeks and then having it adjusted inside your eye. That is the idea behind the light-adjustable lens. The Light Adjustable Lens (LAL, RxSight) has a final power that can be changed after implantation using ultraviolet light, to match what the patient actually needs. The adjustment range is about plus or minus 2.00 D of sphere and 2.00 D of cylinder, which covers most leftover refractive errors. Once the desired result is reached, it is "locked in" and the lens stops being adjustable. A newer version, LAL+, has a slightly modified front surface that extends depth of focus a little, even before any light treatment.
What 2026 research shows. The largest real-world data set so far was published this year in the Journal of Cataract & Refractive Surgery. This post-marketing registry enrolled 1,101 patients (2,202 eyes) across 126 sites. 586 eyes had previous laser vision correction and 1,616 did not. Across all outcome measures there was no significant difference between the two groups. For example, sharp near reading vision (J1) with both eyes, using a blended-vision approach, was reached by 82% of patients with prior laser surgery and 85% of those without. The authors reported that uncorrected distance and near vision were better than historical results with fixed-power lenses.
That finding matters for one group in particular: people who had LASIK years ago. Their eyes are notoriously hard to calculate lens power for, and an adjustable lens gives the surgeon a second chance to get it right.
The scale is growing. By April 2026, more than 300,000 of these lenses had been implanted worldwide. RxSight has also announced a next-generation platform, including toric versions, designed to need fewer light treatments after surgery.
The bigger news of 2026. In July, Alcon and RxSight announced a partnership to combine light adjustability with presbyopia-correcting optics. Alcon will pay $60 million upfront, with up to $140 million more as development and regulatory milestones are met. RxSight will develop and manufacture the lens, and Alcon will lead global sales. In simple terms, a future multifocal or extended-range lens could be fine-tuned after surgery, letting surgeons correct a refractive surprise without exchanging the lens or doing laser treatment on the cornea.
The honest trade-offs. Adjustable lenses need several clinic visits for light treatments, and patients wear UV-protective glasses until the final lock-in. They are not yet available everywhere. The company lists regulatory approvals in North America, Europe, Singapore, South Korea and Australia; India is not yet on that list.
2. Accommodating Lenses: An Implant That Changes Focus Like a Young Lens
This is the oldest goal in lens design: an implant that actually focuses, the way your natural lens did at 25. Early attempts were disappointing. Despite decades of development, few accommodating designs have shown durable, reproducible focusing in rigorous trials, and regulatory approvals have generally relied on safety and visual acuity rather than objective measurement of accommodation. The UK's NICE guidance on accommodating lenses, updated in 2026, reviewed trials showing better near vision than standard lenses in some studies, but also recorded capsule clouding that needed laser treatment in some eyes.
Multifocal and extended-depth lenses are different again. They widen the range of vision by spreading light, but they do not restore true focusing.
The new generation of accommodating lenses works differently from the old ones. Instead of a rigid lens that tries to slide forward and back, most are fluid-filled, shape-changing lenses that sit in the natural lens capsule and respond to the eye's own focusing muscle.
The most encouraging 2026 data. At the ASCRS meeting in April, Atia Vision presented three-year results for its OmniVu lens system. The lens has two parts: a fluid-filled base that changes shape in response to the eye's focusing mechanism, and a front lens that carries the patient's prescription. The study included 19 patients (29 eyes). At 36 months, average refraction stayed within plus or minus 0.50 D. With both eyes, average uncorrected vision was 20/16 for distance, 20/20 for intermediate and 20/25 (J1) for near, and vision of 20/32 or better was maintained across roughly 5 dioptres of focus range. Only one laser capsulotomy was needed across all eyes, and no lens exchanges were required. The lens has received FDA approval to begin a US feasibility study.
The numbers are small, but three years of stability in a shape-changing lens is meaningful. Earlier designs often lost their effect over time.
Alcon's fluid lens is close to a readout. Alcon's randomised trial comparing its fluid accommodating lens with a standard monofocal lens has an estimated primary completion date of November 2026. The study enrolled 175 patients at sites in Costa Rica, the Dominican Republic, Mexico and Panama. A separate Alcon feasibility study of a newer accommodating design began in December 2025 in Central America, with completion expected around October 2026.
One accommodating lens is already available in Europe. The Lumina lens (AkkoLens) takes a different approach. It sits just in front of the capsular bag, in a space called the sulcus, and has two optical plates that slide sideways across each other as the eye's focusing muscle works. It is CE-marked and available on a limited basis in Europe. Studies have measured up to about 2 to 2.5 dioptres of genuine focusing, and in a pilot study the effect lasted at least two years. Because it sits outside the capsular bag, it avoids the capsule scarring that weakened earlier designs.
Further back in the pipeline, the JelliSee lens uses a soft gel designed to copy the lens of a child. Unusually, its focusing is meant to be helped, not hindered, by the natural tightening of the capsule after surgery. It has so far been implanted in a small number of patients outside the US.
In the US, the only approved accommodating lenses remain older designs that are rarely used today.
A note of caution. Not every announcement deserves equal weight. In February 2026, a Canadian company reported first-in-human results for its own accommodating lens. Independent reviewers noted that no numerical data had been disclosed, there was no trial registry entry, follow-up was short, and the regulatory pathway was undefined. When you read headlines about a "revolutionary" lens, look for published numbers, registered trials and follow-up longer than a few months.
Why this matters to patients. A lens that focuses by changing shape does not split light. If these designs succeed in larger trials, they could offer a full range of vision with the night-time clarity of a standard lens.
3. Telescopic Implants: Help for Advanced Macular Degeneration
This is the area closest to my own work as a retina surgeon, and the one patients least often hear about.
In advanced age-related macular degeneration (AMD), the centre of the retina is permanently damaged. Injections can control the wet form, but once scarring or atrophy sets in, central vision does not come back. A telescopic implant does not repair the retina. It magnifies the image so that it falls on healthier retina around the damaged centre.
The leading device is the SING IMT (Smaller-Incision New-Generation Implantable Miniature Telescope). In January 2026, an 81-year-old woman in Melbourne became the first patient at her hospital to receive this implant, which provides 2.7 times magnification. Her surgeon was clear that it does not restore vision, but after rehabilitation and training it helped her recognise faces and read large print.
New 2026 research. One major limitation has been that the telescope was designed to replace the natural lens, so patients who had already had cataract surgery, which is most elderly AMD patients, were not eligible. A 2026 paper in the International Journal of Retina and Vitreous described a way around this. Surgeons in Italy placed the telescope in front of the existing lens implant in two patients. Both surgeries went smoothly, vision improved by 3 to 4 lines on the chart, and corneal cell loss was under 5% at six months. A randomised international trial called PERSPECTIVE is now comparing placing the telescope on top of the existing lens with replacing that lens, and it is expected to enrol participants through 2026.
Who might be a candidate? This is a carefully selected treatment. The US pivotal study requires patients aged 65 or older with vision between 20/160 and 20/800 in both eyes from geographic atrophy or scarring, and no active abnormal blood vessels for at least six months. Telescopes also reduce peripheral field and image contrast, so typically only one eye is treated and the other keeps its side vision. The most common risks are inflammatory deposits on the device and raised eye pressure. Structured low-vision rehabilitation afterwards is essential.
4. Further Out: Reshaping a Lens That Is Already Inside Your Eye
One more idea deserves a mention. A company called Perfect Lens is developing a low-energy femtosecond laser technique that changes the optical properties of almost any standard acrylic lens, rather than requiring a special implant. In laboratory work it could modify up to 4.00 D of spherical power and 3.00 D of astigmatism. In theory, someone who had cataract surgery years ago could have their existing lens fine-tuned in the clinic. However, human experience so far is limited to two patients treated in Panama in 2018. This remains experimental.
What to Watch in 2027
Technology | Where it stands (October 2026) | What to watch in 2027 |
Light-adjustable lens (monofocal) | Approved in several countries; more than 300,000 implanted | Next-generation version needing fewer light treatments; wider international approvals |
Light-adjustable multifocal lens (Alcon and RxSight) | Development began July 2026 | Early design and trial news. A launch in 2027 is unlikely |
Fluid accommodating lenses (Alcon, Atia OmniVu) | Randomised and feasibility trials finishing late 2026; OmniVu entering a US feasibility study | Publication of full trial results; decisions on pivotal trials |
Sulcus accommodating lens (Lumina) | CE-marked; limited availability in Europe | Wider European use and longer follow-up data |
Telescopic implant (SING IMT) | Approved in Europe; US pivotal and pseudophakic trials ongoing | Results for patients who already have a lens implant |
Laser reshaping of existing lenses | Early experimental stage | Larger human studies, if any |
What This Means If You Need Cataract Surgery Now
My advice is simple. Do not postpone cataract surgery that is affecting your daily life in the hope of a future lens. Most of these technologies are still years from routine availability in India, and today's lenses, including toric, extended-range and trifocal designs, give excellent results when chosen well.
What matters most is choosing the right lens for your eye, and that decision depends heavily on retinal health. A patient with early macular degeneration, diabetic retinopathy or an epiretinal membrane may do poorly with a light-splitting multifocal lens that would suit someone else perfectly. A detailed retinal scan (OCT) before lens selection is, in my view, essential for any premium lens decision. At Claritas Eye and Retina, this retina-first assessment is part of how we plan every cataract surgery.
And if you have advanced macular degeneration and have been told nothing more can be done, ask about low-vision options, including whether newer devices like telescopic implants might ever be suitable for you.
Frequently Asked Questions
Is the light-adjustable lens available in India?
At the time of writing, the manufacturer lists approvals in North America, Europe, Singapore, South Korea and Australia. India is not yet on that list.
Are accommodating lenses better than multifocal lenses?
Newer designs show promising early results, including good near vision without light-splitting. One of them, the Lumina lens, is CE-marked and available on a limited basis in Europe; the fluid-filled designs are still investigational. Larger, longer trials are needed before any of them can be recommended over today's proven lenses.
Can a telescopic implant cure macular degeneration?
No. It magnifies images onto healthier parts of the retina and can improve function in carefully selected patients, but it does not repair the damaged retina. Rehabilitation training is essential.
Should I wait for these new lenses before having cataract surgery?
Generally, no. If cataract is affecting your vision and daily life, current lens options provide excellent outcomes. Most of the technologies described here are not expected to be widely available in the near term.
Can my existing lens implant be adjusted later?
Not with current routine technology. Laser-based reshaping of implanted lenses is being researched but remains experimental.
References
Schallhorn J, Rajanala A. Clinical outcomes of patients bilaterally implanted with the Light Adjustable Lens: results of a Phase IV clinical registry. J Cataract Refract Surg. 2026.
Pellegrini M, Adamo GG, et al. Add-on implantation of the smaller-incision new generation implantable miniature telescope (SING IMT) in pseudophakic eyes. Int J Retina Vitreous. 2026;12:28. PMID 41578358.
Wiley WF. Durability of visual and refractive outcomes with a modular shape-changing IOL. Presented at ASCRS Annual Meeting, April 2026.
ClinicalTrials.gov: NCT05317728 and NCT07147192 (Alcon fluid accommodating IOL studies); NCT07164378 (PERSPECTIVE); NCT05438732 (CONCERTO).
NICE. Implantation of accommodating intraocular lenses for cataract (HTG134). 2026.
Alcon and RxSight joint press release, 6 July 2026.
EuroTimes (ESCRS). The Quest for True Accommodation; So Near, Yet So Far. 2026.
About the author: Dr Mayank Bansal is a vitreoretinal surgeon and Director of Claritas Eye & Retina Institute, New Delhi. He trained at AIIMS, holds FRCS (Glasgow) and FACS, and completed a fellowship at UCLA's Stein Eye Institute.
This article is for general education and does not replace a personal consultation.
Comments